DEA Resists Testimony From Agency Official Linked To Report On Marijuana's Harms During Rescheduling Hearing
The DEA is resisting a request from Smart Approaches to Marijuana to have agency official Luli Akinfiresoye testify on the harms of marijuana. The agency's own witness list includes an FDA official and a doctor who will discuss medical benefits for pain patients. The hearing on the Trump administration's rescheduling move began Monday, June 23.
What changed
The DEA has moved to block testimony from an agency official linked to a report on marijuana harms.
Live updates
-
DEA Blocks Anti-Cannabis Testimony in Rescheduling Hearing
confidence 90%The DEA is resisting a request from Smart Approaches to Marijuana to have agency official Luli Akinfiresoye testify on the harms of marijuana. The agency's own witness list includes an FDA official and a doctor who will discuss medical benefits for pain patients. The hearing on the Trump administration's rescheduling move began Monday, June 23.
What's confirmed:
- The DEA is resisting a request from the group Smart Approaches to Marijuana for agency official Luli Akinfiresoye to testify about the harms of marijuana.
- The DEA witness list for the rescheduling hearing includes an FDA official and a doctor who will testify that medical marijuana provides a medical benefit to pain patients.
- The federal rescheduling hearing began on Monday, June 23.
- The DEA denied requests from NORML and other cannabis groups to participate in the rescheduling hearings.
Still unconfirmed:
- The DEA's refusal to provide prohibitionist testimony signals potential agency alignment with rescheduling efforts.
- Marijuana Moment and other media outlets are pushing for the DEA to livestream the rescheduling hearing.